Phase I, dose-escalating trial to evaluate the tolerability and pharmacokinetics of single ascending oral doses of NGX 426

Trial Profile

Phase I, dose-escalating trial to evaluate the tolerability and pharmacokinetics of single ascending oral doses of NGX 426

Recruiting
Phase of Trial: Phase I

Latest Information Update: 13 May 2008

At a glance

  • Drugs Dasolampanel (Primary)
  • Indications Migraine; Neuropathic pain
  • Focus Adverse reactions
  • Sponsors TorreyPines Therapeutics Inc
  • Most Recent Events

    No Data Available
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top